Manufacturing

Suzanne Shelley is a contributing editor to 

Articles

Makers of specialty biologics, gene therapies, and other personalized medicines are working to identify and reduce potential supply chain risks both upstream and downstream.

Reducing Vulnerabilities in Upstream and Downstream Supply Chains

Siegfried Schmitt, PhD, is Vice President Technical at Parexel International, Siegfried.Schmitt@parexel.com.

Good distribution practices ensure appropriate physical storage, distribution, and supply chain security, says Siegfried Schmitt, vice president, Technical, at Parexel.

Securing the Supply Chain with Good Distribution Practices

There is an evolution in the way technology and best practices are blended to meet cold-chain supply requirements for temperature-sensitive biotherapeutics.

Combining Engineering Ingenuity with Managerial Excellence to Safeguard Biologics

Efforts to optimize the ideal blend of technology and best practices that are needed to protect and deliver time- and temperature-sensitive biologic therapies, vaccines, and cell and gene therapies continue to evolve. 

Safeguarding Biologics— Blending Engineering Ingenuity  and Managerial Excellence

Chris Spivey is the editorial director of 

mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.

mRNA Hauptbahnhof

Etihad Cargo is one of the only airlines to hold IATA CEIV Pharma certification globally. 

Etihad Cargo Achieves IATA CEIV Pharma Recertification for Pharmaceutical Logistics

High-cost-per-dose large molecules can make a big impact on cell and gene therapy supply chain management.

Drug Product Security

The newly formed partnership between CSafe and BioLife will expand cold chain supply chain solutions for the cell and gene therapy market.

CSafe and BioLife Solutions Partnership Will Expand Supply Chain for Cell and Gene Therapies

Mahesh Veerina is the president and CEO of ParkourSC.

Technological developments in real-time supply chain operations provide biologics manufacturers with capabilities that go beyond supply chain visibility to tangibly address security and quality challenges. 

Advances in Real-Time Supply Chain Operation Technology Can Address Drug Product Security Challenges

Cleo Bern Hartley is a pharma consultant, former pharma analyst, and research scientist.

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Supply Chain/Logistics